Polyelectrolyte-coated nanocapsules containing undecylenic acid: Synthesis, biocompatibility and neuroprotective properties

Colloids and Surfaces B: Biointerfaces

Volumn 135, Issue , 2015, Pages 8-17

  Piotrowski, Marek ^a   Jantas, Danuta ^b   Szczepanowicz, Krzysztof ^a   Lukasiewicz, Sylwia ^c   Lasoń, Władysław ^b   Warszyński, Piotr ^a  

^a INSTITUTE OF CATALYSIS AND SURFACE CHEMISTRY   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Biocompatibility; Nanoencapsulation; Neuroprotection; Polyelectrolytes; SH SY5Y; Undecylenic acid

Indexed keywords

BIOCOMPATIBILITY; CELL CULTURE; CELLS; CYTOLOGY; POLYELECTROLYTES;

CORE-SHELL NANOCAPSULES; HUMAN NEUROBLASTOMA; LAYER-BY-LAYER TECHNIQUES; NANO-ENCAPSULATION; NEUROPROTECTION; NEUROPROTECTIVE AGENTS; SH-SY5Y; UNDECYLENIC ACID;

NANOCAPSULES;

10 UNDECENOIC ACID; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; LACTATE DEHYDROGENASE; MACROGOL; NANOCAPSULE; NANOCOATING; POLYELECTROLYTE; BIOMATERIAL; DRUG CARRIER; ELECTROLYTE; NEUROPROTECTIVE AGENT; STAUROSPORINE;

ARTICLE; BIOCOMPATIBILITY; CELL ASSAY; CELL TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; EMULSION; ENZYME RELEASE; EXCIPIENT COMPATIBILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; NANOENCAPSULATION; NANOFABRICATION; NEUROBLASTOMA CELL LINE; NEUROPROTECTION; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL; ANTAGONISTS AND INHIBITORS; CELL DEATH; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG STABILITY; MATERIALS TESTING; SYNTHESIS; TUMOR CELL LINE;

BIOCOMPATIBLE MATERIALS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG STABILITY; ELECTROLYTES; HUMANS; MATERIALS TESTING; NANOCAPSULES; NEUROPROTECTIVE AGENTS; PARTICLE SIZE; STAUROSPORINE; UNDECYLENIC ACIDS;

EID: 84938074945     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2015.07.029     Document Type: Article

References (56)

1. Re F., Gregori M., Masserini M. Nanotechnology for neurodegenerative disorders. Maturitas 2012, 73:45-51.
2. Praticò D., Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am. J. Med. 2000, 109:577-585.
3. Czogalla A., Sikorski A.F. Spectrin and calpain: a 'target' and a 'sniper' in the pathology of neuronal cells. Cell Mol. Life Sci. 2005, 62:1913-1924.
4. Lee E., Eom J.E., Kim H.L., Baek K.H., Jun K.Y., Kim H.J., Lee M., Mook-Jung I., Kwon Y. Effect of conjugated linoleic acid, mu-calpain inhibitor, on pathogenesis of Alzheimer's disease. Biochim. Biophys. Acta 2013, 1831:709-718.
5. Ray S.K., Banik N.L. Calpain and its involvement in the pathophysiology of CNS injuries and diseases: therapeutic potential of calpain inhibitors for prevention of neurodegeneration. Curr. Drug Targets CNS Neurol. Disord 2003, 2:173-189.
6. Beija M., Salvayre R., Lauth-de Viguerie N., Marty J. Colloidal systems for drug delivery: from design to therapy. Trends Biotechnol. 2012, 30:485-496.
7. Bicker J., Alves G., Fortuna A., Falcão A. Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. Eur. J. Pharm. Biopharm. 2014, 87:409-432.
8. Costantino L., Boraschi D. Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents. Drug Discov. Today 2012, 17:367-378.
9. Haidar Z.S. Bio-inspired/-functional colloidal core-shell polymeric-based nanosystems: technology promise in tissue engineering, bioimaging and nanomedicine. Polymers 2010, 2:323-352.
10. Kreuter J. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know. Adv. Drug Deliv. Rev. 2014, 71:2-14.
11. Piotrowski M., Szczepanowicz K., Jantas D., Leśkiewicz M., Lasoń W., Warszyński P. Emulsion-core and polyelectrolyte-shell nanocapsules: biocompatibility and neuroprotection against SH-SY5Y cells. J. Nanopart. Res. 2013, 15.
12. Antipina M.N., Sukhorukov G.B. Remote control over guidance and release properties of composite polyelectrolyte based capsules. Adv. Drug Deliv. Rev. 2011, 63:716-729.
13. Delcea M., Möhwald H., Skirtach A.G. Stimuli-responsive LbL capsules and nanoshells for drug delivery. Adv. Drug Deliv. Rev. 2011, 63:730-747.
14. Shchukina E.M., Shchukin D.G. LbL coated microcapsules for delivering lipid-based drugs. Adv. Drug Deliv. Rev. 2011, 63:837-846.
15. Shutava T.G., Pattekari P.P., Arapov K.A., Torchilin V.P., Lvov Y.M. Architectural layer-by-layer assembly of drug nanocapsules with PEGylated polyelectrolytes. Soft Matter 2012, 8:9418-9427.
16. Szczepanowicz K., Hoel H.J., Szyk-Warszynska L., Bielańska E., Bouzga A.M., Gaudernack G., Simon C., Warszynski P. Formation of biocompatible nanocapsules with emulsion core and pegylated shell by polyelectrolyte multilayer adsorption. Langmuir 2010, 26:12592-12597.
17. Kabanov A.V., Gendelman H.E. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog. Polym. Sci. 2007, 32:1054-1082.
18. Jang S., Liu W., Song W., Chiang K., Ma H., Kao C., Chen M. Nanomedicine-based neuroprotective strategies in patient specific-iPSC and personalized medicine. Int. J. Mol. Sci. 2014, 15:3904-3925.
19. Kakran M., Antipina M.N. Emulsion-based techniques for encapsulation in biomedicine, food and personal care. Curr. Opin. Pharmacol. 2014, 18:47-55.
20. Shchukin D.G., Shchukina E. Capsules with external navigation and triggered release. Curr. Opin. Pharmacol. 2014, 18:42-46.
21. Salvador-Morales C., Zhang L., Langer R., Farokhzad O.C. Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 2009, 30:2231-2240.
22. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307:93-102.
23. Jokerst J.V., Lobovkina T., Zare R.N., Gambhir S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond.) 2011, 6:715-728.
24. Łukasiewicz S., Szczepanowicz K.P., Błasiak E., Dziedzicka-Wasylewska M. Biocompatible polymeric nanoparticles as promising candidates for drug delivery. Langmuir 2015, 10.1021/acs.langmuir.5b01226.
25. Rotman M., Welling M.M., Bunschoten A., de Backer M.E., Rip J., Nabuurs R.J., Gaillard P.J., van Buchem M.A., van der Maarel S.M., van der Weerd L. Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease. J. Control. Release 2015, 203:40-50.
26. Begley D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther 2004, 104:29-45.
27. Woolf N., Priel A., Tuszynski J. Nanotechnology, Nanostructure, and Nervous System Disorders 2015, 177-226. Springer Berlin Heidelberg, 2010.
28. Stockwell J., Abdi N., Lu X., Maheshwari O., Taghibiglou C. Novel central nervous system drug delivery systems. Chem. Biol. Drug Des. 2014, 83:507-520.
29. Lee E., Eom J.E., Kim H.L., Kang D.H., Jun K.Y., Jung D.S., Kwon Y. Neuroprotective effect of undecylenic acid extracted from Ricinus communis L. through inhibition of mu-calpain. Eur. J. Pharm. Sci. 2012, 46:17-25.
30. Jantas D., Piotrowski M., Lasoń W. An involvement of PI 3-K/Akt activation and inhibition of AIF translocation in neuroprotective effects of undecylenic acid (UDA) against pro-apoptotic factors-induced cell death in human neuroblastoma SH-SY5Y cells. J. Cell. Biochem. 2015, 10.1002/jcb.25236.
31. Szczepanowicz K., Dronka-Góra D., Para G., Warszyński P. Encapsulation of liquid cores by layer-by-layer adsorption of polyelectrolytes. J. Microencapsul. 2010, 27:198-204.
32. Szczepanowicz K., Podgórna K., Szyk-Warszyńska L., Warszyński P. Formation of oil filled nanocapsules with silica shells modified by sequential adsorption of polyelectrolytes. Colloids Surf. Physicochem. Eng. Aspects 2014, 441:885-889.
33. Adamczak M., Hoel H.J., Gaudernack G., Barbasz J., Szczepanowicz K., Warszyński P. Polyelectrolyte multilayer capsules with quantum dots for biomedical applications. Colloids Surf. B: Biointerfaces 2012, 90:211-216.
34. Adamczak M., Krok M., Pamuła E., Posadowska U., Szczepanowicz K., Barbasz J., Warszyński P. Linseed oil based nanocapsules as delivery system for hydrophobic quantum dots. Colloids Surf. B: Biointerfaces 2013, 110:1-7.
35. Bazylińska U., Skrzela R., Szczepanowicz K., Warszyński P., Wilk K.A. Novel approach to long sustained multilayer nanocapsules: influence of surfactant head groups and polyelectrolyte layer number on the release of hydrophobic compounds. Soft Matter 2011, 7:6113-6124.
36. Bazylińska U., Skrzela R., Piotrowski M., Szczepanowicz K., Warszyński P., Wilk K.A. Influence of dicephalic ionic surfactant interactions with oppositely charged polyelectrolyte upon the in vitro dye release from oil core nanocapsules. Bioelectrochemistry 2012, 87:147-153.
37. Decher G. Fuzzy nanoassemblies: toward layered polymeric multicomposites. Science 1997, 277:1232-1237.
38. Sukhorukov G.B., Donath E., Lichtenfeld H., Knippel E., Knippel M., Budde A., Möhwald H. Layer-by-layer self assembly of polyelectrolytes on colloidal particles. Colloids Surf. Physicochem. Eng. Aspects 1998, 137:253-266.
39. Hermanson G.T. Fluorescent probes. Bioconjugate Techniques 2013, 395-463. Academic Press, Boston, (Chapter 10). Third ed. G.T. Hermanson (Ed.).
40. Łukasiewicz S., Szczepanowicz K. In vitro interaction of polyelectrolyte nanocapsules with model cells. Langmuir 2014, 30:1100-1107.
41. Palamà I.E., Coluccia A.M.L., Torre A.D., Vergaro V., Perrone E., Cingolani R., Rinaldi R., Leporatti S. Multilayered polyelectrolyte capsules and coated colloids: cytotoxicity and uptake by cancer cells. Sci. Adv. Mater. 2010, 2:138-150. (2010-06-01T00:00:00).
42. Jantas D., Pytel M., Mozrzymas J.W., Leśkiewicz M., Regulska M., Antkiewicz-Michaluk L., Lasoń W. The attenuating effect of memantine on staurosporine-, salsolinol- and doxorubicin-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurochem. Int. 2008, 52:864-877.
43. Jantas D., Lorenc-Koci E., Kubera M., Lasoń W. Neuroprotective effects of MAPK/ERK1/2 and calpain inhibitors on lactacystin-induced cell damage in primary cortical neurons. Neurotoxicology 2011, 32:845-856.
44. Adamczak M., Kupiec A., Jarek E., Szczepanowicz K., Warszyński P. Preparation of the squalene-based capsules by membrane emulsification method and polyelectrolyte multilayer adsorption. Colloids Surf. Physicochem. Eng. Aspects 2014, 462:147-152.
45. Szczepanowicz K., Dronka- Góra D., Para G., Bouzga A.M., Simon C., Yang J., Warszyński P. Chloroform emulsions containing TEOS, APS and DTSACl as cores for microencapsulation. Procedia Chem. 2009, 1:1576-1583.
46. Szczepanowicz K., Bazylińska U., Pietkiewicz J., Szyk-Warszyńska L., Wilk K.A., Warszyński P. Biocompatible long-sustained release oil-core polyelectrolyte nanocarriers: from controlling physical state and stability to biological impact. Adv. Colloid Interface Sci. 2014.
47. Sharma H.S., Sharma A. New perspectives of nanoneuroprotection, nanoneuropharmacology and nanoneurotoxicity: modulatory role of amino acid neurotransmitters, stress, trauma, and co-morbidity factors in nanomedicine. Amino Acids 2013, 45:1055-1071.
48. Holder A.L., Goth-Goldstein R., Lucas D., Koshland C.P. Particle-induced artifacts in the MTT and LDH viability assays. Chem. Res. Toxicol. 2012, 25:1885-1892.
49. Xie H.R., Hu L.S., Li G.Y. SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease. Chin. Med. J. (Engl.) 2010, 123:1086-1092.
50. Lopes F.M., Schroder R., da Frota M.L., Zanotto-Filho A., Muller C.B., Pires A.S., Meurer R.T., Colpo G.D., Gelain D.P., Kapczinski F., Moreira J.C., Fernandes Mda C., Klamt F. Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies. Brain Res. 2010, 1337:85-94.
51. Fotakis G., Timbrell J.A. In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol. Lett. 2006, 160:171-177.
52. Weyermann J., Lochmann D., Zimmer A. A practical note on the use of cytotoxicity assays. Int. J. Pharm. 2005, 288:369-376.
53. Ulery B.D., Nair L.S., Laurencin C.T. Biomedical applications of biodegradable polymers. J. Polym. Sci. B: Polym. Phys. 2011, 49:832-864.
54. Facca S., Cortez C., Mendoza-Palomares C., Messadeq N., Dierich A., Johnston A.P.R., Mainard D., Voegel J.-, Caruso F., Benkirane-Jessel N. Active multilayered capsules for in vivo bone formation. Proc. Natl. Acad. Sci. 2010, 107:3406-3411.
55. Gunatillake P.A., Adhikari R. Biodegradable synthetic polymers for tissue engineering, Eur. Cell. Mater. 2003, 5:1-16. discussion 16.
56. Westwood M., Roberts D., Parker R. Enzymatic degradation of poly-l-lysine-polygalacturonic acid multilayers. Carbohydr. Polym. 2011, 84:960-969.